Description

Certara, Inc.: Is The Biosimulation & Software Growth Here To Stay? 

Certara reported robust financial performance for the fourth quarter and full year of 2024, reflecting a 9% growth in revenue to $385.1 million compared to the previous year. The company experienced a stronger growth trajectory in the fourth quarter, with revenues reaching $100.4 million, marking a 14% year-over-year increase. This growth was primarily fueled by a substantial 26% increase in software revenue, attributed to the robust demand for their biosimulation software and contributions from the recent acquisition of Chemaxon, which added $6.6 million to the reported revenue.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!